Driving Under the InfluenceREVELIONCT07401628
In-Vehicle Real-Time Cannabis Influenced Driving Detection
A study testing Cannabis (THC) in people with Driving Under the Influence and Cannabis-impaired Driving, run by University of Bern at 1 site in Switzerland.
Trial summary
The goal of this clinical trial is to evaluate whether in-vehicle sensor data can be used to detect cannabis-impaired driving in healthy adult recreational cannabis users. The study aims to assess whether changes in vehicle, driver, and physiological sensor data can distinguish sober driving from cannabis-impaired… Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Driving Under the Influence, Cannabis-impaired Driving
- What is being tested?
- Cannabis (THC)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteSwitzerland
- Study dates
- 5 Jan 2026to 14 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Informed consent as documented by signature
- Recreational cannabis-consumption (more than once per month)
- In possession of a definite Swiss or European Union (EU) driving license
- At least 21 years old
- Active, regular driving a car in the last 6 months
- Must be in good health condition
- No special equipment needed when driving (special seats, levers, etc.)
- Fluent in (Swiss) German and no speech impairment
Who cannot join
- Health concerns where cannabis consumption is contra-indicated (such as: high blood pressure, psychiatric problems (e.g. psychosis, depression, attention-deficit conditions, etc.)
- Cannabis-abstinence or excessive consumption, , assessed using the Cannabis Use Disorders Identification Test-Revised (CUDIT-R)
- For women: pregnancy or breastfeeding or if intention to become pregnant during study period (time between telephone screening and study day (visit 2)
- Alcohol misuse or excessive alcohol consumption habits/risky drinking behaviour, assessed using the Alcohol Use Disorders Identification Test (AUDIT) and/or phosphatidylethanol (PEth) in capillary blood > 200 ng/mL at first visit
- If breath alcohol test is positive at Visit 1 or Visit 2 (study day)
- Consumption of drugs of abuse (others than cannabis) within 4 weeks before the study
- Consumption of medications / pharmaceutical drugs which interfere with driving ability
- Inability to follow the procedures of the study, e.g., due to language
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Institute for Forensic Medicine, Forensic Chemistry and Toxicology University of Bern
Bern, 3008
About this study
Official title: Randomised, Controlled, Interventional Single-center Study for the Design and Evaluation of an In-vehicle Real-time System for Detecting Cannabis-impaired Driving (CID)
The goal of this clinical trial is to evaluate whether in-vehicle sensor data can be used to detect cannabis-impaired driving in healthy adult recreational cannabis users.
The study aims to assess whether changes in vehicle, driver, and physiological sensor data can distinguish sober driving from cannabis-impaired driving, and how driving performance changes from baseline to approximately 1 to 6 hours after controlled cannabis consumption.
Read more
Researchers will compare driving behavior and in-vehicle sensor data from participants who receive controlled cannabis administration with data from a randomized reference group without cannabis exposure, to determine whether cannabis-related impairment driving can be identified on the basis of machine learning.
Participants will complete screening and baseline assessments and drive an instrumented vehicle on a closed test track under sober conditions. Participants assigned to the experimental arm will receive controlled cannabis administration, while participants in the reference arm will receive no intervention. All participants will perform repeated standardized driving sessions over several hours and complete traffic-medical, traffic-psychological, and in-vehicle pre-driving tests. Biological samples and in-vehicle sensor data will be collected throughout the study.
- Being tested
- Cannabis (THC)
- Medical subject headings
- Driving Under the Influence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cannabis (THC)Drug
Participants assigned to the experimental arm receive a single, controlled inhalative administration of cannabis by smoking a THC-containing joint (target dose 0.67 mg THC per kg body weight; cannabis flowers with 15-18% THC).
| Study group | Role | What they receive |
|---|---|---|
| Controlled Cannabis Administration | Experimental | Participants assigned to this arm receive a single, controlled inhalative administration of cannabis by smoking a THC-containing joint with a target dose of approximately 0.67 mg THC per kg body weight. Participants complete standardized driving sessions in an instrumented vehicle on a closed test track under sober baseline conditions and repeatedly after cannabis administration (approximately 1-6 hours post-dose). All driving sessions are conducted with a certified driving instructor seated in the front passenger seat with access to dual pedals, allowing immediate intervention if required. Multimodal in-vehicle sensor data, physiological signals, driving performance measures, and biological samples are collected throughout the study. Receives: Drug: Cannabis (THC) |
| Reference (No Cannabis) | No intervention | Participants assigned to this reference arm receive no cannabis administration. They complete the same screening procedures, standardized driving sessions, assessments, and data collection as the experimental group under sober conditions, following the same schedule and time points. All driving sessions are conducted with a certified driving instructor seated in the front passenger seat with access to dual pedals, ensuring identical safety conditions. This arm serves as a non-impaired reference for comparison of driving behavior and in-vehicle sensor data. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic accuracy (AUROC) of a multimodal machine-learning model for detection of cannabis-impaired driving
Area under the receiver operating characteristic curve (AUROC) of a single machine-learning classifier that integrates multimodal in-vehicle data (including vehicle controller area network [CAN] data, driver monitoring camera [DMC] features, and physiological signals). All modalities are combined into one predictive model, and performance is reported as one aggregated AUROC value distinguishing non-impaired (sober) driving from cannabis-impaired driving.
Measured: Baseline (sober driving) and up to 6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Secondary outcomes (17)
Diagnostic accuracy (AUROC) using CAN data
AUROC for detecting cannabis-impaired driving using vehicle controller area network (CAN) data only.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Diagnostic accuracy (AUROC) using DMC data
AUROC for detecting cannabis-impaired driving using driver monitoring camera (DMC) data only.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Diagnostic accuracy (AUROC) of a physiology-based machine-learning model for detection of cannabis-impaired driving
AUROC of a single machine-learning classifier trained and evaluated using aggregated physiological features only, derived from signals including heart rate, heart-rate variability, oxygen saturation, electrodermal activity, skin temperature, and respiration-related measures. All physiological signals are combined into one predictive model, and performance is reported as a single AUROC value distinguishing non-impaired (sober) driving from cannabis-impaired driving.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in driving behavior derived from vehicle CAN data
Change in driving behavior between sober driving and post-cannabis driving, derived from vehicle controller area network (CAN) signals, including steering, braking, acceleration, and velocity-related measures.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in driver gaze behavior derived from DMC data
Change in gaze behavior between sober and post-cannabis driving, derived from driver monitoring camera (DMC) data, including gaze direction and gaze dynamics during driving.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in head movement behavior derived from DMC data
Change in head movement behavior between sober and post-cannabis driving, derived from driver monitoring camera (DMC) data.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Driving instructor assessment of driving performance
Assessment of driving performance conducted by a certified driving instructor, quantified as the number of safety interventions required during each standardized driving session.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Diagnostic accuracy (AUROC) of an in-vehicle pre-driving readiness test for detection of cannabis-impaired driving
AUROC of a machine-learning (ML) classification model implementing a study-specific in-vehicle pre-driving readiness test. The test produces an ML-derived readiness score, computed from features derived from the pre-driving test (e.g., attention-related, reaction-time-related, and psychomotor-related features), and is used to classify driving sessions as sober versus post-cannabis.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Performance in the standardized Psytest assessment
Performance in the standardized Psytest assessment (mobility version of the Test of Attentional Performance), administered under sober conditions and after cannabis consumption. Test performance is summarized using a standardized test score reflecting overall attentional and psychomotor performance relevant for driving.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Self-reported subjective effects
Self-reported subjective effects assessed using study questionnaires, including subjective feeling of "high" and degree of sleepiness. Responses are recorded using a Likert scale ranging from 0 to 10, where 0 indicates "not at all" and 10 indicates "extremely." Higher scores indicate a worse outcome, reflecting stronger subjective drug effects and greater sleepiness.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Cannabinoid biomarker concentrations in biological samples
Concentrations of Δ9-tetrahydrocannabinol (THC) measured in capillary blood, oral fluid, and breath samples.
Measured: Baseline in all participants, and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm.
Incidence of adverse events
Incidence of adverse events and serious adverse events recorded during all study visits.
Measured: From the first study procedure (i.e. baseline assessment) to the end of the main study day (i.e. driving assessment) expected to be on average up to 6 hours.
Change in heart rate during driving
Change in heart rate measured during driving between sober conditions and post-cannabis conditions.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in oxygen saturation during driving
Change in oxygen saturation measured during driving between sober conditions and post-cannabis conditions.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in electrodermal activity during driving
Change in electrodermal activity measured during driving between sober conditions and post-cannabis conditions.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in skin temperature during driving
Change in skin temperature measured during driving between sober conditions and post-cannabis conditions.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in respiration during driving
Change in respiration measured during driving between sober conditions and post-cannabis conditions.
Measured: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2026
- Study start5 Jan 2026
- Primary completion14 Jul 2026
- Study completion14 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Driving Under the InfluenceStudies of the same condition, open and under way.
- More trials run by University of BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Bern
- Sponsor type
- University, hospital or other
- Collaborators
- ETH Zurich, University of St.Gallen
- Responsible party
- Sponsor
- Investigators
- Wolfgang Weinmann, Prof. Dr., Principal investigator, Institute for Forensic Medicine, Forensic Chemistry and Toxicology University of Bern
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07401628
- Sponsor's protocol ID
- 2025-01590
- Other IDs
- 2025
- Acronym
- REVELIO
- Status last verified
- Jul 2026
- First submitted
- 22 Jan 2026
- Last updated
- 20 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Deuber R, Bechny M, Heck C, Brugger J, Pfaffli M, Jovanova M, Fleisch E, Wortmann F, Weinmann W. Protocol for the REVELIO test-track pilot study: A randomised, controlled, single-centre trial in healthy recreational cannabis users investigating real-time in-vehicle detection of cannabis-impaired driving. PLoS One. 2026 Oct 1;21(10):e0349328. doi: 10.1371/journal.pone.0349328. eCollection 2026.
PubMed 42821661
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomised, Controlled, Interventional Single-center Study for the Design and Evaluation of an In-vehicle Real-time System for Detecting Cannabis-impaired Driving (CID)
- ClinicalTrials.gov ID
- NCT07401628
- Acronym / sponsor ID
- REVELIO / 2025-01590
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- University of BernUniversity, hospital or other
- Collaborators
- ETH Zurich, University of St.Gallen
- Study start
- 5 Jan 2026 (actual)
- Primary completion
- 14 Jul 2026 (actual)
- Study completion
- 14 Jul 2026 (actual)
- First posted
- 10 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether in-vehicle sensor data can be used to detect cannabis-impaired driving in healthy adult recreational cannabis users.
The study aims to assess whether changes in vehicle, driver, and physiological sensor data can distinguish sober driving from cannabis-impaired driving, and how driving performance changes from baseline to approximately 1 to 6 hours after controlled cannabis consumption.
Researchers will compare driving behavior and in-vehicle sensor data from participants who receive controlled cannabis administration with data from a randomized reference group without cannabis exposure, to determine whether cannabis-related impairment driving can be identified on the basis of machine learning.
Participants will complete screening and baseline assessments and drive an instrumented vehicle on a closed test track under sober conditions. Participants assigned to the experimental arm will receive controlled cannabis administration, while participants in the reference arm will receive no intervention. All participants will perform repeated standardized driving sessions over several hours and complete traffic-medical, traffic-psychological, and in-vehicle pre-driving tests. Biological samples and in-vehicle sensor data will be collected throughout the study.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Controlled Cannabis Administration | Experimental | Drug: Cannabis (THC)Participants assigned to this arm receive a single, controlled inhalative administration of cannabis by smoking a THC-containing joint with a target dose of approximately 0.67 mg THC per kg body weight. Participants complete standardized driving sessions in an instrumented vehicle on a closed test track under sober baseline conditions and repeatedly after cannabis administration (approximately 1-6 hours post-dose). All driving sessions are conducted with a certified driving instructor seated in the front passenger seat with access to dual pedals, allowing immediate intervention if required. Multimodal in-vehicle sensor data, physiological signals, driving performance measures, and biological samples are collected throughout the study. |
| Reference (No Cannabis) | No intervention | –Participants assigned to this reference arm receive no cannabis administration. They complete the same screening procedures, standardized driving sessions, assessments, and data collection as the experimental group under sober conditions, following the same schedule and time points. All driving sessions are conducted with a certified driving instructor seated in the front passenger seat with access to dual pedals, ensuring identical safety conditions. This arm serves as a non-impaired reference for comparison of driving behavior and in-vehicle sensor data. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Informed consent as documented by signature
- Recreational cannabis-consumption (more than once per month)
- In possession of a definite Swiss or European Union (EU) driving license
- At least 21 years old
- Active, regular driving a car in the last 6 months
Key exclusion criteria (8 listed)
- Health concerns where cannabis consumption is contra-indicated (such as: high blood pressure, psychiatric problems (e.g. psychosis, depression, attention-deficit conditions, etc.)
- Cannabis-abstinence or excessive consumption, , assessed using the Cannabis Use Disorders Identification Test-Revised (CUDIT-R)
- For women: pregnancy or breastfeeding or if intention to become pregnant during study period (time between telephone screening and study day (visit 2)
- Alcohol misuse or excessive alcohol consumption habits/risky drinking behaviour, assessed using the Alcohol Use Disorders Identification Test (AUDIT) and/or phosphatidylethanol (PEth) in capillary blood > 200 ng/mL at first visit
- If breath alcohol test is positive at Visit 1 or Visit 2 (study day)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cannabis (THC)Participants assigned to the experimental arm receive a single, controlled inhalative administration of cannabis by smoking a THC-containing joint (target dose 0.67 mg THC per kg body weight; cannabis flowers with 15-18% THC). | Drug | Controlled Cannabis Administration |
Primary outcome
Diagnostic accuracy (AUROC) of a multimodal machine-learning model for detection of cannabis-impaired driving
Time frame: Baseline (sober driving) and up to 6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Area under the receiver operating characteristic curve (AUROC) of a single machine-learning classifier that integrates multimodal in-vehicle data (including vehicle controller area network [CAN] data, driver monitoring camera [DMC] features, and physiological signals). All modalities are combined into one predictive model, and performance is reported as one aggregated AUROC value distinguishing non-impaired (sober) driving from cannabis-impaired driving.
17 secondary outcomes
Diagnostic accuracy (AUROC) using CAN data
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Diagnostic accuracy (AUROC) using DMC data
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Diagnostic accuracy (AUROC) of a physiology-based machine-learning model for detection of cannabis-impaired driving
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in driving behavior derived from vehicle CAN data
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in driver gaze behavior derived from DMC data
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in head movement behavior derived from DMC data
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Driving instructor assessment of driving performance
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Diagnostic accuracy (AUROC) of an in-vehicle pre-driving readiness test for detection of cannabis-impaired driving
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Performance in the standardized Psytest assessment
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Self-reported subjective effects
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Cannabinoid biomarker concentrations in biological samples
Time frame: Baseline in all participants, and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm.
Incidence of adverse events
Time frame: From the first study procedure (i.e. baseline assessment) to the end of the main study day (i.e. driving assessment) expected to be on average up to 6 hours.
Change in heart rate during driving
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in oxygen saturation during driving
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in electrodermal activity during driving
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in skin temperature during driving
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Change in respiration during driving
Time frame: Baseline (sober driving) and approximately 1-2, 3-4, and 5-6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2026.
- Derived from this study: PubMed 42821661Deuber R, Bechny M, Heck C, Brugger J, Pfaffli M, Jovanova M, Fleisch E, Wortmann F, Weinmann W. Protocol for the REVELIO test-track pilot study: A randomised, controlled, single-centre trial in healthy recreational cannabis users investigating real-time in-vehicle detection of cannabis-impaired driving. PLoS One. 2026 Oct 1;21(10):e0349328. doi: 10.1371/journal.pone.0349328. eCollection 2026.
- Individual participant dataSharing planned: No
Related trials for Driving Under the Influence
Recruiting
Concentrations of Nitrous Oxide in Blood, Exhaled Air and Urine After Various Types of Exposure.
Intoxication by Drug
Active, not recruitingPhase 1
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
Cannabis, Alcohol Effect
Active, not recruitingPhase 1
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
Cannabis, Alcohol Effect
Active, not recruitingPhase 1
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
Cannabis, Alcohol Effect
Active, not recruitingPhase 1
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
Cannabis, Alcohol Effect
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wolfgang Weinmann, Prof. Dr. principal investigator
Institute for Forensic Medicine, Forensic Chemistry and Toxicology University of Bern
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cannabis (THC) in people with Driving Under the Influence and Cannabis-impaired Driving, run by University of Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnostic accuracy (AUROC) of a multimodal machine-learning model for detection of cannabis-impaired driving (time frame: Baseline (sober driving) and up to 6 hours after cannabis administration in the experimental arm, with matched time points in the reference arm.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07401628, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2026.